TELA Bio, Inc. (TELA)

Over the past six months, TELA Bio's stock experienced a share price decline of 59.03%. In Q3 2025, the company reported revenue of $20.7 million, a 9% increase year-over-year, and a net loss of $8.6 million. The company revised its full-year 2025 revenue guidance to at least 16% growth. TELA Bio strengthened its capital structure with a new credit facility of up to $70.0 million and completed a sales organization realignment. The company announced inducement grants related to new-hire equity grants and filed to sell 2 million shares of common stock. Analysts cut their forecasts on TELA Bio following Q3 earnings.

Analysis of TELA Bio's seasonal stock charts suggests a potential seasonal pattern, with a "Buy Date of December 5 and a Sell Date of February 24" showing a geometric average return of 17.68% above the S&P 500 Total Return Index. This seasonal timeframe has shown positive results in 5 out of 5 periods. However, it is cautioned that only five years of data are available, which may be insufficient to create a reliable seasonal profile. Furthermore, this seasonal timeframe correlates poorly with the broader Healthcare sector's period of seasonal strength. Factors that can cause fluctuations in quarterly and annual results include surgeon and patient adoption of products, timing of new product offerings, changes in reimbursement policies, pricing pressure, and the ability to expand geographic reach.

TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions within the Healthcare sector, specifically the Medical Devices and Surgical Devices industry. The company aims to optimize clinical outcomes by preserving and restoring a patient's own anatomy, leveraging their natural healing response while minimizing long-term exposure to permanent synthetic materials. TELA Bio's major products include OviTex Reinforced Tissue Matrix for hernia repair and abdominal wall reconstruction, OviTex PRS Reinforced Tissue Matrix for plastic and reconstructive surgery, OviTex LPR for laparoscopic and robotic-assisted hernia repairs, TIGR Matrix (acquired in July 2023) as a fully synthetic, resorbable mesh, and ReCOVR™ a resorbable adhesive technology.

TELA Bio primarily markets its products through a direct sales force in the United States. The company also engages in international sales and is pursuing aggressive expansion in Europe. Its corporate office is located in Malvern, Pennsylvania, United States.

TELA Bio's brand reputation is built around its commitment to innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The company emphasizes leveraging the patient's natural healing response and minimizing the use of permanent synthetic materials. Their corporate communications consistently highlight their core product advantage: a reinforced biologic material that works with the body. There is no specific information available regarding events that have negatively impacted TELA Bio's brand reputation in the past year.

TELA Bio's ownership is largely dominated by institutional and major insider-affiliated investors, who collectively hold over 60% of the company's common stock as of November 2025. Major institutional owners include Nantahala Capital Management, LLC, Essex Woodlands Management, Inc., Silverarc Capital Management, Llc, Stonepine Capital Management, LLC, Vanguard Group Inc, DAFNA Capital Management LLC, Perkins Capital Management Inc, BlackRock, Inc., and Citigroup Inc. As of November 17, 2025, insiders held 4.70% of the stock, while institutions held 94.35%.